Immune-related adverse events, survival outcomes, and next steps in patients with stage III melanoma: real-world experience at a National Cancer Institute-designated Comprehensive Cancer Center
Our findings do not support an association between irAEs and survival in patients with stage III melanoma. However, specific types of events, particularly hepatitis, may increase mortality. Prospective studies are needed to clarify optimal treatment after recurrence.
Authors
- Hailey Seibert (ORCID: https://orcid.org/0000-0003-3545-3766)
- Jonathan Boone
- Matthew M. Mirsky (ORCID: https://orcid.org/0000-0001-8737-9882)
- Seunghee Margevicius (ORCID: https://orcid.org/0000-0001-5663-8319)
- Kevin Zablonski (ORCID: https://orcid.org/0009-0004-2655-6418)
- Ankit Mangla (ORCID: https://orcid.org/0000-0002-6789-4315)
- Richard S. Hoehn (ORCID: https://orcid.org/0000-0003-1455-6758)
- Maira A Bhatty (ORCID: https://orcid.org/0000-0002-2936-2799)
- Pingfu Fu (ORCID: https://orcid.org/0000-0002-2334-5218)
- Luke Daniel Rothermel (ORCID: https://orcid.org/0000-0001-5700-8028)
- Natalie Chakraborty
- Iris Yeong- Fung Sheng (ORCID: https://orcid.org/0009-0007-4999-6733)
- Débora S. Bruno
Institutions
- University Hospitals of Cleveland (US)
- University Hospitals Cleveland Medical Center (US)
- University Hospitals Seidman Cancer Center (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1093/oncolo/oyaf393
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00